Funding
Cancer
HEART, CANCER
The ASCEND study is funded by grants to the University of Oxford from the British Heart Foundation (SP/03/002, SP/08/010/25939, SP/14/3/31114, PG/05/013/18296). The Clinical Trial Service Unit at the University of Oxford receives support from the UK Medical Research Council (which funds the MRC Population Health Research Unit in a strategic partnership with the University of Oxford, MC_UU_00017/3, MC_UU_00017/5), the British Heart Foundation, and Cancer Research UK. Bayer Pharma AG, Solvay, Abbott, and Mylan provided the active and placebo drug and funding for drug packaging and Bayer Healthcare LLC contributed to funding. The design of the study and collection, analysis, and interpretation of data and writing of the manuscript were carried out independently of the funding bodies. For the purpose of open access, the authors have applied a Creative Commons Attribution (CC BY) license to any Author Accepted Manuscript version arising.